The Imperative of Biopharma Growth for Cancer Cure and Beyond
The diagnosis of cancer in a loved one is a devastating blow, a stark reminder of the disease's long-standing reign as the "emperor of maladies." For much of modern medical history, cancer was nearly incurable, with treatments often proving as toxic to patients as to the disease itself. However, the past two decades have ushered in a dramatic transformation, driven by the advent of biological therapies, or biologics.
The Rise of Biologics in Modern Medicine
Scientists have learned to harness living systems to develop biologics, which include antibodies and engineered proteins. These drugs target specific pathways that cancer cells rely on for growth and survival, offering greater precision, reduced toxicity, and enhanced effectiveness compared to traditional chemical drugs. As a result, long-term remissions and even cures are becoming increasingly common for several types of cancer.
This revolution extends beyond oncology. Patients with conditions such as asthma, rheumatoid arthritis, inflammatory bowel disease, and other autoimmune disorders now benefit from biologic therapies. Even genetic disorders, once deemed untreatable, are being addressed through advanced approaches like gene therapy.
The Access Challenge in India
Despite these advancements, for most Indians, cancer and many other serious illnesses remain as devastating and incurable as in the past. The primary barrier is access. Biological therapies are prohibitively expensive, with treatment costs running into crores, placing them out of reach for the majority of patients. This often leads to delayed, interrupted, or never-initiated treatments, turning potentially curable diseases into fatal ones.
India's pharmaceutical landscape highlights this stark contrast. While the country has built a globally respected generic drug industry, it has not kept pace in the biologics era. Biosimilars, which are similar to biologic medicines but not exact copies due to the complexity of biologics produced in living cells, offer a solution. When developed and regulated rigorously, biosimilars provide the same clinical benefits as original biologics at significantly lower costs, serving as the closest equivalent to generics in this advanced therapeutic domain.
Biopharma Shakti: A Strategic Shift
In this context, the Union Budget's Biopharma Shakti initiative—Strategy for Healthcare Advancement through Knowledge, Technology and Innovation—assumes critical importance. It represents a shift in India's pharmaceutical ambition from being primarily a global supplier of chemical generics to becoming a hub for biopharmaceutical manufacturing and innovation.
The initiative focuses on:
- Strengthening research institutions
- Expanding clinical trial capacity
- Upgrading regulatory expertise
- Investing in complex manufacturing infrastructure
These measures directly address the structural barriers that have limited biosimilar development in India. If implemented effectively, the potential gains are substantial, making advanced therapies widely accessible.
Mission Mode Thinking and Execution
However, ambition alone is insufficient. A mission mode approach, akin to how ISRO tackles space technology, is required across diverse stakeholders. Investment in skills and quality systems is paramount, as biologics manufacturing tolerates little error and demands sustained emphasis on training and quality control at institutions that must be adequately prepared.
Moreover, innovation must not be overshadowed by cost-cutting alone. A successful biosimilar ecosystem should serve as a bridge from affordability today to original biologic innovation tomorrow. The science is ready, and high-level policy choices have been made. What is needed now are lower-level policy decisions that enable the ecosystem to execute effectively, ranging from ease of doing science at research institutions to ease of doing business for the industry.
Biopharma Shakti is a welcome announcement with a progressive vision, but only its execution will determine whether advanced medicine remains a privilege or becomes a public good in India.
